We therefore analyzed the role of these cytokines in TLR9-mediated prevention of early plasmacytoma development by treating mice with the neutralizing F3 anti-IFN-γ mAb and a specific anti-IL-12 mAb recognizing the heterodimeric cytokine (MM12A1.6) (23). The gene discussed is IFNG; the disease is plasmacytoma.